Integrating Cellular Metabolism into a Multiscale Whole-Body Model

Cellular metabolism continuously processes an enormous range of external compounds into endogenous metabolites and is as such a key element in human physiology. The multifaceted physiological role of the metabolic network fulfilling the catalytic conversions can only be fully understood from a whole-body perspective where the causal interplay of the metabolic states of individual cells, the surrounding tissue and the whole organism are simultaneously considered. We here present an approach relying on dynamic flux balance analysis that allows the integration of metabolic networks at the cellular scale into standardized physiologically-based pharmacokinetic models at the whole-body level. To evaluate our approach we integrated a genome-scale network reconstruction of a human hepatocyte into the liver tissue of a physiologically-based pharmacokinetic model of a human adult. The resulting multiscale model was used to investigate hyperuricemia therapy, ammonia detoxification and paracetamol-induced toxication at a systems level. The specific models simultaneously integrate multiple layers of biological organization and offer mechanistic insights into pathology and medication. The approach presented may in future support a mechanistic understanding in diagnostics and drug development.

[1]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[2]  Francis H. McCrudden Uric Acid: The Chemistry, Physiology and Pathology of Uric Acid and the Physiologically Important Purin Bodies, with a Discussion of the Metabolism in Gout , 2010 .

[3]  N. Vermeulen,et al.  Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. , 1992, Drug metabolism reviews.

[4]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[5]  Markus J. Herrgård,et al.  Integrating high-throughput and computational data elucidates bacterial networks , 2004, Nature.

[6]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[7]  M. Wenk,et al.  Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities , 1999, European Journal of Clinical Pharmacology.

[8]  U. Sauer,et al.  Large-scale 13C-flux analysis reveals mechanistic principles of metabolic network robustness to null mutations in yeast , 2005, Genome Biology.

[9]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[10]  Stefan Willmann,et al.  Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide , 2012, Molecular Diagnosis & Therapy.

[11]  Luke Hunter,et al.  Interpreting Metabolomic Profiles using Unbiased Pathway Models , 2010, PLoS Comput. Biol..

[12]  Kathryn A. Phillips,et al.  Diagnostics and biomarker development: priming the pipeline , 2006, Nature Reviews Drug Discovery.

[13]  Jonathan C. Cohen,et al.  Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. , 2010, Journal of hepatology.

[14]  L. Kuepfer,et al.  Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.

[15]  S. Schuster,et al.  Analysis of structural robustness of metabolic networks. , 2004, Systems biology.

[16]  Carmen G. Moles,et al.  Parameter estimation in biochemical pathways: a comparison of global optimization methods. , 2003, Genome research.

[17]  William M. Lee,et al.  Acetaminophen‐induced acute liver failure: Results of a United States multicenter, prospective study , 2005, Hepatology.

[18]  G Levy,et al.  Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. , 1984, Journal of pharmaceutical sciences.

[19]  Erwin P. Gianchandani,et al.  Dynamic Analysis of Integrated Signaling, Metabolic, and Regulatory Networks , 2008, PLoS Comput. Biol..

[20]  Frederick Van Lente,et al.  Correlation between ammonia levels and the severity of hepatic encephalopathy. , 2003, The American journal of medicine.

[21]  J. Doyle,et al.  Bow Ties, Metabolism and Disease , 2022 .

[22]  Matthias Hermes,et al.  Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration , 2010, Proceedings of the National Academy of Sciences.

[23]  O. Demin,et al.  The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.

[24]  H. J. Greenberg,et al.  Monte Carlo sampling can be used to determine the size and shape of the steady-state flux space. , 2004, Journal of theoretical biology.

[25]  F. Doyle,et al.  Dynamic flux balance analysis of diauxic growth in Escherichia coli. , 2002, Biophysical journal.

[26]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  J. Wahren,et al.  Ammonia metabolism during exercise in man. , 1985, Clinical physiology.

[28]  E. Ruppin,et al.  Predicting metabolic biomarkers of human inborn errors of metabolism , 2009, Molecular systems biology.

[29]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[30]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[31]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[32]  Aarash Bordbar,et al.  A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology , 2011, BMC Systems Biology.

[33]  B. Palsson,et al.  Genome-scale models of microbial cells: evaluating the consequences of constraints , 2004, Nature Reviews Microbiology.

[34]  L F Prescott,et al.  Kinetics and metabolism of paracetamol and phenacetin. , 1980, British journal of clinical pharmacology.

[35]  Lei Shi,et al.  Synthesis of Resveratrol Analogues, and Evaluation of Their Cytotoxic and Xanthine Oxidase Inhibitory Activities , 2008, Chemistry & biodiversity.

[36]  K. Heard,et al.  Acetylcysteine for acetaminophen poisoning. , 2008, The New England journal of medicine.

[37]  F. Larsen,et al.  Persistent Arterial Hyperammonemia Increases the Concentration of Glutamine and Alanine in the Brain and Correlates with Intracranial Pressure in Patients with Fulminant Hepatic Failure , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  U. Sauer,et al.  Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli , 2007, Molecular systems biology.

[39]  Roger Harrison,et al.  Structure and function of xanthine oxidoreductase: where are we now? , 2002, Free radical biology & medicine.

[40]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[41]  Stefan Willmann,et al.  Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. , 2012, Molecular diagnosis & therapy.

[42]  L. Kuepfer Towards whole-body systems physiology , 2010, Molecular systems biology.

[43]  N E Maestri,et al.  Plasma glutamine concentration: a guide in the management of urea cycle disorders. , 1992, The Journal of pediatrics.

[44]  J. Selbig,et al.  Parallel analysis of transcript and metabolic profiles: a new approach in systems biology , 2003, EMBO reports.

[45]  Jason A. Papin,et al.  Genome-scale microbial in silico models: the constraints-based approach. , 2003, Trends in biotechnology.

[46]  B. Ross,et al.  Severity of Hyperammonemic Encephalopathy Correlates with Brain Ammonia Level and Saturation of Glutamine Synthetase In Vivo , 1996, Journal of neurochemistry.

[47]  C. Gille,et al.  HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology , 2010, Molecular systems biology.

[48]  R. Oberbauer,et al.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. , 1999, British journal of clinical pharmacology.

[49]  Nicola Brunetti-Pierri,et al.  Inborn errors of metabolism: the flux from Mendelian to complex diseases , 2006, Nature Reviews Genetics.

[50]  Lars Kuepfer,et al.  Multiscale mechanistic modeling in pharmaceutical research and development. , 2012, Advances in experimental medicine and biology.

[51]  Alan H. Lockwood,et al.  Blood Ammonia Levels and Hepatic Encephalopathy , 2004, Metabolic Brain Disease.

[52]  W. Schmitt,et al.  A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.

[53]  Walter Schmitt,et al.  Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.

[54]  Laura P James,et al.  Acetaminophen‐Induced Hepatotoxicity: Role of Metabolic Activation, Reactive Oxygen/Nitrogen Species, and Mitochondrial Permeability Transition , 2004, Drug metabolism reviews.

[55]  Tatsuo Hosoya,et al.  [Hyperuricemia and gout]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[56]  Stefan Willmann,et al.  Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[57]  Nan Xiao,et al.  Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli , 2008, Bioinform..

[58]  Simeone Marino,et al.  Understanding the Immune Response in Tuberculosis Using Different Mathematical Models and Biological Scales , 2005, Multiscale Model. Simul..

[59]  Yoshiaki Matsumoto,et al.  Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. , 2007, Biological & pharmaceutical bulletin.

[60]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[61]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[62]  Kay Brune,et al.  Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[64]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[65]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[66]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[67]  Stefan Willmann,et al.  Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. , 2012, British journal of clinical pharmacology.

[68]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[69]  An-Ping Zeng,et al.  The Connectivity Structure, Giant Strong Component and Centrality of Metabolic Networks , 2003, Bioinform..

[70]  I. Goryanin,et al.  Human metabolic network reconstruction and its impact on drug discovery and development. , 2008, Drug discovery today.

[71]  D. Bergel Geigy Scientific Tables , 1991 .

[72]  C. Szabó,et al.  Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.

[73]  D. Kell,et al.  High-throughput classification of yeast mutants for functional genomics using metabolic footprinting , 2003, Nature Biotechnology.

[74]  M. Williams,et al.  Purinergic and pyrimidinergic receptors as potential drug targets. , 2000, Biochemical pharmacology.

[75]  J. Leonard,et al.  Urea cycle disorders. , 2002, Seminars in neonatology : SN.

[76]  E. Ruppin,et al.  Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism , 2010, Molecular systems biology.

[77]  L. James,et al.  Mechanisms of acetaminophen-induced liver necrosis. , 2010, Handbook of experimental pharmacology.

[78]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[79]  G. Murrell,et al.  Clinical Pharmacokinetics of Allopurinol , 1986, Clinical pharmacokinetics.

[80]  Ian David Lockhart Bogle,et al.  Addressing the challenges of multiscale model management in systems biology , 2007, Comput. Chem. Eng..

[81]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[82]  Lars M. Blank,et al.  Metabolic flux distributions: genetic information, computational predictions, and experimental validation , 2010, Applied Microbiology and Biotechnology.